Stock Track | Glaukos (GKOS) Plummets 13.2% as Wider Q4 Loss Disappoints Investors

Stock Track

Feb 21, 2025

Shares of Glaukos (GKOS) plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.

Glaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to the significant stock decline.

Additionally, Glaukos forecasted full-year 2025 sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1160015608"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160015608\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160015608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-21 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160015608","market":"us","top_or_hot":-1,"title":"Stock Track | Glaukos (GKOS) Plummets 13.2% as Wider Q4 Loss Disappoints Investors","media":"Stock Track","content":"<p>Shares of Glaukos (GKOS) plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.</p>\n\n<p>Glaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to the significant stock decline.</p>\n\n<p>Additionally, Glaukos forecasted full-year 2025 sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Glaukos (GKOS) Plummets 13.2% as Wider Q4 Loss Disappoints Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Glaukos (GKOS) Plummets 13.2% as Wider Q4 Loss Disappoints Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-21 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Glaukos (GKOS) plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.</p>\n\n<p>Glaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to the significant stock decline.</p>\n\n<p>Additionally, Glaukos forecasted full-year 2025 sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"","article_id":"1160015608","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160015608","pubTimestamp":1740148679,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Glaukos  plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.Glaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"由于第四季度亏损扩大令投资者失望，股票追踪Glaukos(GKOS)暴跌13.2%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Shares of Glaukos (GKOS) plunged 13.2% in the pre-market trading session on Friday, February 21, 2025, as the medical technology firm reported a wider-than-expected net loss for the fourth quarter of 2024.\nGlaukos posted a net loss of $22.2 million for the quarter, larger than the Wall Street estimate of a $20.8 million loss. While the company recorded revenue of $105.5 million, slightly above expectations of $100.7 million, the larger-than-anticipated loss appears to have spooked investors, leading to the significant stock decline.\nAdditionally, Glaukos forecasted full-year 2025 sales in the range of $475 million to $485 million, compared to the consensus estimate of $479.8 million. The company's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}